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The current success of targeted inhibition against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and
Programmed Death 1/Programmed Death Ligand 1 (PD-1/PD-L1, herein collectively referred to as PD) pathways is
hailed as a cancer immunotherapy breakthrough. PD-L1, known also as B7 homolog 1 (B7-H1), was initially discovered
by Dr. Lieping Chen in 1999. To recognize the seminal contributions by Chen to the development of PD-directed
therapy against cancer, the Chinese American Hematologist and Oncologist Network (CAHON) decided to honor him
with its inaugural Lifetime Achievement Award in Hematology and Oncology at the CAHON’s 2015 annual meeting.
This essay chronicles the important discoveries made by Chen in the exciting field of immuno-oncology, which goes
beyond his original fateful finding. It also argues that PD-directed therapy should be appropriately considered as
Tumor-Site Immune Modulation Therapy to distinguish it from CTLA-4-based immune checkpoint blocking agents.
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Monoclonal antibodies targeting the PD pathway have
become a critical breakthrough in our long fight against
cancer [1, 2]. Distinct from any previous anti-cancer
drugs, PD-based cancer therapy neither directly targets
tumors, nor simply revamps the immune system non-
specifically. It depends on the strategic modulation of a
key tumor immune evasive mechanism featured by the
PD-L1 (B7-H1) molecule, and controls tumor growth by
resetting immune responses in the tumor microenviron-
ment to the homeostatic and beneficial level [3, 4]. Cur-
rently, several anti-PD therapeutic agents have been
approved for the treatment of multiple cancer types in-
cluding lung cancer, head and neck cancer, melanoma and
others in the United States, Europe, as well as in Japan
and other parts of the world. Numerous clinical trials are
ongoing worldwide in order to broaden and increase the
utility of anti-PD therapeutics to most if not all human* Correspondence: zihai@musc.edu
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favorable toxicities of these novel agents. The successful
development of PD-modulating medicines has revolu-
tionized the field of immuno-oncology in an unprece-
dented way, and opens the door for Tumor-Site Immune
Modulation Therapy [5] that will profoundly impact basic
and clinical immune-oncology research. Indeed, many
outstanding reviews have been written on this topic
[3–12]. Nevertheless, in this essay, we review the key
milestones in the history of anti-PD drug develop-
ment, and specifically highlight some of Lieping
Chen’s contributions to this revolutionary cancer
treatment modality.History of anti-PD drug development and the roles of
Lieping Chen
The success of anti-PD drug development benefited
from the advancement of our fundamental understand-
ing of both cancer biology and the immune system. Can-
cer originates from the mutated self of the host in the
setting of genotoxic insults with molecular hallmarks of
genetic instability and heterogeneity [13, 14]. Most con-
ventional therapies, including radiation, chemotherapyle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Timeline for major events leading to the development of
anti-PD drugs. The contributions by Lieping Chen are highlighted in
light orange. The contributions by Lieping Chen are highlighted in
light orange
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cancers themselves with improving, but still less desir-
able efficacy due to significant side-effects, drug resist-
ance and recurrence of more aggressive malignant
clones [8, 13, 15]. The limitations of conventional ther-
apies are especially evident for late stage and advanced
cancers. In contrast, the immune system, especially the
adaptive arm of immunity such as T cells, is capable of
surveilling against mutated antigens in tumor cells and
controlling tumor growth through specific immune ef-
fector mechanisms. Importantly, these immune cells
evolve in parallel with tumors, and are capable of sustain-
able tumor recognition and killing [16, 17]. However, sur-
veillance efficacy often fails due to multiple tumor immune
evasive mechanisms, resulting in the outgrowth and metas-
tasis of cancer cells [18, 19]. Efforts in understanding the
basic mechanisms of immune tolerance in general and the
primary immune evasive mechanisms by cancer cells in
particular have been the key to the successful development
of drugs targeting the PD-1/PD-L1 pathway.
Many individuals contributed to the success of PD-
directed cancer therapy (Table 1 and Fig. 1) [2]. Among
them, Lieping Chen’s work is the focus of this review. In
the early span of the 1990s, Chen was convinced that in
the tumor microenvironment, there exist specific mo-
lecular pathways that are primarily responsible for im-
mune evasion, and that this concept could be harnessed
for more effective cancer therapy. His passion has been
devoted towards the search for these elusive molecules
ever since. Trained as a physician-scientist in China,
Chen quickly became convinced that basic medical re-
search holds the key to cancer cure. He earned his M.S.
degree at the Cancer Institute of Peking Union Medical
College in 1986 before obtaining his Ph.D. from Drexel
University in 1989. He then undertook his postdoctoral
training at the University of Washington, Seattle in
1990, all along focusing on immunology. During that
period, important discoveries were made regarding the
major immune cell populations with different immune
functions, distinguished by cell surface molecules,Table 1 Major contributions to the development of targeted cancer i
Contributions CTLA-4 PD-1
Gene Cloning Pierre Goldstein (1987) [59] Tasuku Ho
Inhibitory Function Jeffery Bluestone (1994) [30]
Arlene Sharpe (1995) [32]
Tak Mak (1995) [33]
Tasuku Ho
Ligand-receptor Interaction Peter Linsley (1991) [25] Tasuku Ho
Function in cancer immunity James Allison (1996) [34] NagahiroM
Lieping C
Tasuku Ho
a The discovery of PD-L2 was made by Gordon Freeman and Arlene Sharpe (2001)[6
highlighted here
b Gordon Freeman, Andrew Long and Yoshiko Iwai are the three co-first authors ofincluding CD3, CD4, CD8, T cell receptor (TCR) and
others [20–23]. More importantly, the guiding principle
of T cell activation and tolerance began to emerge [21].
Among those important events, the discovery of CD28,
CTLA-4 and their ligands B7 (B7.1 and B7.2) was the
key development in the field [24, 25] which vindicated
the two-signal hypothesis for lymphocyte activation
proposed by Bretscher and Cohn [26], and extended by
Lafferty and his colleagues [27]. The first signal is via TCR
triggered by an MHC-antigenic peptide complex, whereas
the second signal, also known as a co-stimulation signal, is
provided by co-stimulatory molecules expressed on the
surface of antigen presenting cells (APC) and T cells (like
B7-CD28 pathway). Based on this principle, Chen and hismmunotherapeutics against CTLA-4 and PD-1/PD-L1 Pathways a
PD-L1 (B7-H1)
njo (1992) [57] Lieping Chen (1999) [47]
njo (1999) [60] Lieping Chen (1999) [47]
Tasuku Honjo, Clive Wood (2000) [57] b
Lieping Chen (2004) [68]




Lieping Chen (2002) [56]
Nagahiro Minato (2002) [63]
1], and Drew Pardoll (2001)[62]. Subsequent work on PD-L2 is not
this work, which renamed B7-H1 (its gene cloned one year earlier) to PD-L1
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enforced expression of B7 molecules in cancer cells elicited
strong anti-tumor immune responses, leading to eradica-
tion of distal tumors [28]. This effect is mainly CD28
dependent: upon ligation of the same B7 ligand, CD28
delivers an essential signal for naïve T cell activation [29],
which is in contrast to the CTLA-4 molecule behaving as a
T cell “checkpoint” receptor with inhibitory activities
[30–33]. Blocking CTLA-4 for immunotherapy of cancer
was later steered by James Allison who has played crucial
roles in the renaissance of cancer immunology [34–37],
whereas Chen’s earlier work laid the groundwork for the
therapeutic potential of manipulating co-stimulatory
molecules against cancer. However, the ectopic expression
of costimulatory molecules like B7 on tumor cells worked
effectively against multiple murine tumor models, its
application is currently limited in cancer patients [38].
Additionally, since both B7 ligands and CD28/CTLA-4
receptors are expressed broadly without tumor specificity
and that they play essential roles in the control of general
immune homeostasis, targeting this pathway could be met
with severe autoimmune toxicities, which was shown to
be the case in the clinical trials of TGN1412, an anti-
CD28 super agonist antibody [39], and the anti-CTLA-4
antibodies, ipilimumab and tremelimumab [40–42]. Chen
was determined to uncover tumor-specific immune eva-
sion mechanisms and find ways to block them.
During his seven-year tenure at Bristol-Myers Squibb
(1990–1997), Lieping Chen evaluated the immune func-
tions and potential anti-tumor effects of many cell sur-
face molecules on T cells, especially 4-1BB (CD137), a
molecule specifically expressed by activated T cells and
serving as another co-stimulatory receptor. The Chen
group were the first to reveal the potent anti-tumor
effect of the anti-4-1BB agonistic antibody in both im-
munogenic and non-immunogenic tumor models [43],
making 4-1BB an attractive target for immuno-oncology
[44]. Some promising results from the anti-4-1BB clin-
ical trials were recently reported [45]. Although the
expression of 4-1BB ligand is relatively broad, 4-1BB ex-
pression could accurately identify tumor-reactive T cells
[46]. Even so, Chen believed that immune-regulatory
molecules with higher tumor specificity remained to be
identified. He returned to academia and joined the Mayo
Clinic to continue searching for these pathways. Inspired
by the progress of the Human Genome Project, Chen
turned to informatics to discover candidate molecules
from the human expressed sequence tag (EST) libraries
based on their predicted homology to B7 family mole-
cules. This effort was incredibly successful; he made
several seminal discoveries of a series of novel B7 family
members, including B7-H1 (PD-L1) [47], B7-H2 [48],
B7-H3 [49], B7-H4 [50], B7-H5 [51], PD-1H (VISTA)
[52] and so on [53–55]. In a series of papers, Chen andhis colleagues completed the fundamental characterization
of the B7-H1’s biological function and provided the
very first proof of anti-tumor effects via blockade of
B7-H1 [47, 56], which mainly serve as a ligand to PD-1
receptor on T cells [57], a molecule discovered earlier
by Tasuku Honjo in Japan [58]. In 2004, Chen joined
the Johns Hopkins University School of Medicine and
collaborated with Suzanne Topalian, Julie Brahmer and
other clinical investigators to initiate the first clinical
trial of anti-PD-1/PD-L1 pathway therapies in patients
with cancer. It was this clinical study that opened the
floodgate of PD-1/PD-L1 pathway-directed cancer
immunotherapy.
The key events that led to the successful development
of anti-CTLA-4 and anti-PD-1/PD-L1 drugs are
chronicled below (Fig. 1 and Table 1):
 From 1990 to 1991, Peter Linsley from the Bristol-
Myers Squibb discovered the interaction between
CD28, CTLA-4, and B7 [24, 25]. The B7 pathway was
later generally considered as an essential co-stimulatory
molecule for naïve T cell activation [21, 54].
 In 1992, by stably expressing B7 molecule in the
tumor cells, Lieping Chen provided the theoretical
basis for the therapeutic potential of manipulating
the expression of co-stimulatory molecules in the
tumor microenvironment for cancer immunotherapy
[28, 29].
 In 1992, Tasuku Honjo cloned the PD-1 gene (Pdcd1)
from immune cell lines undergoing apoptosis [58].
 In 1994, Jeffery Bluestone first identified the
inhibitory function of CTLA-4, and also categorized
CTLA-4 as the first cell surface T cell inhibitory
receptor [30]*.
*Note: During the process of drug development
targeting this molecule, Pierre Goldstein cloned
CTLA-4 gene (Ctla4) [59] and Peter Linsley discov-
ered the receptor-ligand interaction between B7 and
CTLA-4 [25] (Table 1). Arlene Sharpe and Tak Mak
subsequently reported the fatal autoimmune diseases
of Ctla4-deficient mice [32, 33]. James Allison char-
acterized the anti-tumor effect of antibody targeting
CTLA-4 [34]. The anti-CTLA-4 antibody, ipilimu-
mab, was later approved by the U.S. Food and Drug
Administration (FDA) for treatment of melanoma in
2011 [37].
 In 1997, Lieping Chen identified the potent anti-
tumor effect of agonistic antibody targeting 4-1BB,
another co-stimulatory receptor on T cells, which
further inspired the field of cancer immunotherapy
[43].
 Around 1997, given the progress of the Human
Genome Project, Lieping Chen’s group started to
search for B7-like molecules from the human EST
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the members of the B7 family.
 In 1999, Chen cloned the first B7 homolog, the
human B7-H1 gene, and identified its inhibitory ac-
tivity on T cells by inducing IL-10 [47]. During the
following years, Chen’s group also cloned B7-H2 [48],
B7-H3 [49], B7-H4 [50], B7-H5 [51] and PD-1H [52].
 In 1999, Tasuku Honjo discovered that the PD-1
gene (Pdcd1) knockout mice have mild autoimmune
symptoms, which revealed the inhibitory function of
PD-1 in preventing autoimmunity [60].
 In 2000, Tasuku Honjo and Clive Wood discovered
the interaction between B7-H1 and PD-1, and chan-
ged the name of B7-H1 to PD-L1 [57].
 In 2001, Arlene Sharpe and Gordon Freeman
discovered another PD-1 ligand, PD-L2 (Pro-
grammed Death Ligand 2), which also shows inhibi-
tory activity to T cells [61]. Drew Pardoll’s group
identified PD-L2 around the same time, and named
this molecule B7-DC for its specific expression on
dendritic cells [62].
 In 2002, Lieping Chen discovered the critical role of
B7-H1 (PD-L1) as a potential immune evasion
mechanism in the tumor microenvironment. B7-H1
is found to be overexpressed in many human tumor
tissues, but minimally detected in the normal tissues,
which was mainly regulated by IFN-γ [56]. Most im-
portantly, antibody-targeting B7-H1 could restore T
cell function and control tumor growth both in vitro
and in vivo [56]. Subsequent works by Nagahiro
Minato [63] and Weiping Zou [64] further sup-
ported this finding. Moreover, Chen’s study sug-
gested the existence of other receptor(s) for B7-H1,
which was later validated by a follow-up mutation
study made by Chen [65], and finally led to the dis-
covery of B7-1 as another B7-H1 inhibitory receptor
by Arlene Sharpe and Gordon Freeman [66].
 In 2003, Scott Strome and Lieping Chen showed
that B7-H1 overexpression in tumor cells and T cell
activation are two indispensable pre-conditions for
the potent anti-cancer effect of antibodies blocking
this pathway [67].
 In 2004, Lieping Chen discovered that the B7-H1
gene (Cd274) null mice have some spontaneous
accumulation of activated CD8+ T cells in the liver,
but do not have overt autoimmune manifestations.
This work further proved the inhibitory function of
B7-H1 and predicted the acceptable safety profile of
B7-H1-targeted therapy [68]. An independent study
by Arlene Sharpe and Gordon Freeman using Cd274-
deficient mice also proved that PD-L1 negatively regu-
lates T cells [69].
 In 2004, Lieping Chen joined the Johns Hopkins
University School of Medicine, and contributed tothe development of the first-in-human trial concept
on antibodies targeting the PD-1/PD-L1 pathway for
the treatment of advanced cancers.
 In 2005, Lieping Chen demonstrated that antibodies
blocking either B7-H1 or PD-1 could promote anti-
tumor immune responses, and proposed the “Mo-
lecular Shield” mechanism of PD-L1 on tumors that
offers resistance to cytotoxic T lymphocytes (CTL)
[70]. Tasuku Honjo also demonstrated that PD-1
blockade by genetic manipulation or antibody treat-
ment inhibited hematogenous spreading of tumor
cells [71].
 In 2006, Rafi Ahmed characterized a role of the PD-
1/PD-L1 pathway in T cell exhaustion with the
lymphocytic choriomeningitis virus (LCMV) chronic
infection model [72].
 In 2006, the first human cancer clinical trial
targeting the PD-1/PD-L1 pathway was launched in
the Johns Hopkins Hospital.
 In 2010, the first clinical observation on anti-PD-1
treatment was reported by Suzanne Topalian [73].
 In 2012, the results of the first two large anti-PD-1
and anti-PD-L1 clinical trials in the Johns Hopkins
Hospital, the Yale-New Haven Hospital and others
were reported [74, 75].
 In 2006, Lieping Chen’s group developed a sensitive
and effective immunohistochemistry staining
protocol for detecting PD-L1 expression in cancer
cells, and pointed out the value of PD-L1 staining in
tumor sections on the prediction of anti-PD-1/PD-
L1 clinical efficacy in 2012. Chen also refined his
theory on anti-PD-1/PD-L1 therapy by proposing
the adaptive resistance concept [76].
 In 2013, cancer immunotherapy was selected as the
breakthrough of the year by the Science magazine [1, 2].
 In 2014, anti-PD-1 antibodies (nivolumab and pem-
brolizumab) were approved in the United States and
Japan for treatment of advanced metastatic melan-
oma [77], and subsequently for treatment of many
other cancer types in 2015–2016 [78–82].
 In 2016, the anti-PD-L1 antibody, atezolizumab, was
approved by the FDA for the treatment of advanced
urothelial carcinoma and non-small cell lung cancer
[82, 83].
Anti-PD modality and tumor-site immune modulation
therapy
The timeline in the history of anti-PD drug development
(Fig. 1) spans from the understanding of the B7 pathway
in regulating T cell responses to the discovery of the PD
pathway with tumor-site immune modulation properties,
reflecting our increased understanding of both T cell
biology and tumor immunity. This advancement resulted
from the progress of research in the field of both
Fig. 2 Mechanism of the PD pathway in driving tumor-associated
immune evasion. Tumor cells, tumor-associated antigen-presenting
cells (APCs), and stromal cells upregulate PD-L1 in response to on-
going immune responses, mainly through the action of IFN-γ. The
ligation of PD-1 by PD-L1 delivers inhibitory signals to T cells,
leading to T cell anergy, functional exhaustion, and apoptosis. PD-1-
PD-L1 interaction also favors conversion of T cells to the regulatory T
cell (Treg) phenotype with secretion of inhibitory cytokines, such as IL-
10. PD-1 on myeloid cells also impairs dendritic cell functions. In
addition, PD-L1 reversed signaling on tumor cells can serve as a
“Molecular Shield” protecting tumor cells from CTL-mediated killing.
IFN-γR: IFN-γ receptor
Fig. 3 Anti-PD modality: Tumor-site immune modulation therapy.
Anti-PD therapy is mechanistically distinct from anti-CTLA-4 therapy:
the latter affects immune responses more systemically, whereas anti-
PD therapy primarily targets its actions at the tumor site. Anti-PD
modality is thus capable of repairing tumor-induced immune
defects, ultimately leading to resetting of the anti-tumor immunity
to a desirable level. TN: Naïve T cells; TE: T effector cells; Tm: memory
T cells; DC: dendritic cells
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birth of immuno-oncology. Ironically, anti-PD antibodies
did not show clear anti-tumor effects in many animal
models in the early days of research, raising skepticism
among many over their therapeutic application. How-
ever, Lieping Chen and his colleagues proposed that the
potency of anti-PD therapy depends on both the existence
of immune cells especially T cells in the tumor site, as well
as PD-L1 expression by the tumor cells [67, 70, 84].
He steadfastly and passionately championed the clinical
development of agents targeting this pathway. Thus,
Chen played key roles in advancing the anti-PD drug
program in the areas of basic research as well as in
clinical translation (Table 1), for which he was recog-
nized with the 2014 William Coley Award in Basic and
Tumor Immunology [85] (shared with Tasuku Honjo,
Arlene Sharpe and Gordon Freeman), the 2015 Lifetime
Achievement Award in Hematology and Oncology by
CAHON (www.cahon.org, and this paper), and the
2016 American Association of Immunologists (AAI)-
Steinman Award for Human Immunology Research
(http://www.aai.org/Awards/Archive/index.html).
Targeting the PD pathway for treatment of cancer is
unique in several aspects, including the following (Figs. 2
and 3):
First, the action of anti-PD therapy is primarily local-
ized to the tumor site. The ligand for PD-1, PD-L1 (B7-
H1), has high expression on tumor cells. It is absent in
the majority of normal tissues, but could be induced in
the tumor microenvironment by ongoing immune re-
sponses, mostly by the cytokine IFN-γ [3, 56]. This
tumor-localized effect of PD-L1 dictates that the anti-
bodies targeting either ligand or receptor will work in
the tumor microenvironment with ongoing immune re-
sponses. In contrast, PD-L2, another ligand of PD-1, has
weak expression in tumors and is constitutively
expressed by dendritic cells [53, 54]. The expression pat-
tern of PD-L2 likely explains why targeting PD-L2 has
only minor anti-tumor effects, although PD-L2 and PD-
L1 have similar binding affinity to PD-1, and their in-
hibitory effects on T cells in vitro are comparable.
Second, targeting the PD pathway repairs or resets
tumor-associated immune defects. The PD-L1 molecule
is a key mechanism for tumor-mediated immune evasion
[3]. The ligation of PD-L1 to PD-1 causes functional de-
fects in T cells through several different mechanisms
(Fig. 2), including anergy to antigen stimulation [86–88],
functional exhaustion [72], apoptosis [56], induction of
immune suppressor cells [89, 90], and secretion of in-
hibitory cytokines, such as IL-10 [47]. PD-1 on myeloid
cells also impairs dendritic cell functions [91]. In
addition, PD-L1 reverse-signaling on tumor cells was
found to serve as a “Molecular Shield,” protecting the
tumor from killing by CTLs [70, 92]. Importantly, this
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stored by termination of this pathway, especially by the
antibody blockade of either PD-L1 or PD-1 [70]. More-
over, anti-PD therapy may reset the global anti-tumor
immune defects possibly by yet unknown “cascade reac-
tion” mechanisms, as profound and sustainable thera-
peutic effects have been observed in many patients
receiving this therapy [3].
Third, the PD blockade aims to normalize the anti-
tumor immune response but not over-exuberate im-
mune responses in general. Blockade of either PD-L1 or
PD-1 is not to simply amplify immunity, but to re-adjust
the anti-tumor immune responses to a desirable level
(Fig. 3). Given the mild and rare autoimmune symptoms
observed in PD-L1 and PD-1 gene-deficient mice [60, 68]
and weak expression of these molecules by normal tissues
[56, 93], targeting the PD pathway in the tumor settings
will normalize anti-tumor immunity but spare the normal
peripheral tolerance mechanism against self-antigens [3].
Thus, anti-PD treatment has an understandably great
safety window [94].
These abovementioned features of the PD pathway are
very unique among the many pathways currently tested
for cancer immunotherapy. Strictly speaking, PD-1/PD-
L1 is the only known pathway responsible for key
tumor-specific immune evasion mechanisms so far. Yet,
both PD-1/PD-L1 and CTLA-4 are often lumped to-
gether as “immune checkpoints” [6, 8, 31, 95], which is
an immunological term defining a plethora of inhibitory
pathways in the control of physiological immune re-
sponses [6]. This concept does not distinguish the
immune modulating role of anti-PD therapy from the
actions of anti-CTLA-4 therapy [3, 7] (Fig. 3). An alter-
native term of “Tumor-Site Immune Modulation Therapy”
might better describe the attributes of anti-PD therapy
[5], which is characterized by targeting molecules re-
sponsible for tumor-site specific immune evasion mech-
anisms, resetting and restoring the anti-tumor immunity
back to a desirable level. Such action is clearly different
from CTLA-4 blockade, which overdrives systemic T cell
immunity including self-reactive T cell responses.
Lieping Chen continues his journey to discover more
PD-like molecules, aiming to convert human cancers to
chronic and manageable diseases via exploiting the
power of the hardwired immune system. His contribu-
tions to this field have cemented his place in immuno-
oncology.
Acknowledgements
We thank many members of CAHON for stimulating discussions on the
topic.
Funding
Z.L. is supported by the U.S. National Institutes of Health grants DK105033,
CA186866, CA188419 and AI070603.Availability of data and materials
The material supporting the conclusion of this review has been included
within the article.
Authors’ contributions
All authors discussed the topic, contributed to the drafting of the manuscript
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
This is not applicable to this review.
Ethics approval and consent to participate
This is not applicable to this review.
Author details
1Yale University School of Medicine, New Haven, CT 06510, USA. 2Veterans
Health Administration Medical Center, East Orange, NJ 07018, USA. 3The
Chinese American Hematologist and Oncologist Network (CAHON),
Scarsdale, NY 11577, USA. 4New York Medical College, Valhalla, NY 10595,
USA. 5Medical University of South Carolina, Charleston, SC 29425, USA.
Received: 7 January 2017 Accepted: 13 January 2017
References
1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer Immunother Sci.
2013;342(6165):1432–3.
2. Pardoll D. Immunotherapy: it takes a village. Science. 2014;344(6180):149.
3. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present,
and future. J Clin Invest. 2015;125(9):3384–91.
4. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for
cancer therapy: Mechanisms, response biomarkers, and combinations. Sci
Transl Med. 2016;8(328):328rv324.
5. Chen L. From the guest editor: Tumor site immune modulation therapy.
Cancer J. 2014;20(4):254–5.
6. Pardoll DM. The blockade of immune checkpoints in cancer
immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.
7. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune
responses: the unique properties of PD-1 and their advantages for clinical
application. Nat Immunol. 2013;14(12):1212–8.
8. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy:
toward combination strategies with curative potential. Cell. 2015;161(2):
205–14.
9. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity
cycle. Immunity. 2013;39(1):1–10.
10. Lesokhin AM, Callahan MK, Postow MA, Wolchok JD. On being less tolerant:
enhanced cancer immunosurveillance enabled by targeting checkpoints
and agonists of T cell activation. Sci Transl Med. 2015;7(280):280sr281.
11. Boussiotis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint
Pathway. N Engl J Med. 2016;375(18):1767–78.
12. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a
common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):
450–61.
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144(5):646–74.
14. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW.
Cancer genome landscapes. Science. 2013;339(6127):1546–58.
15. Qiao J, Liu Z, Fu YX. Adapting conventional cancer treatment for
immunotherapy. J Mol Med (Berl). 2016;94(5):489–95.
16. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the
tumor microenvironment. Nat Immunol. 2013;14(10):1014–22.
17. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating
immunity’s roles in cancer suppression and promotion. Science. 2011;
331(6024):1565–70.
18. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;
117(5):1137–46.
Wang et al. Journal of Hematology & Oncology  (2017) 10:34 Page 7 of 819. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer
immunoediting and its three component phases–elimination, equilibrium
and escape. Curr Opin Immunol. 2014;27:16–25.
20. Reinherz EL. Revisiting the Discovery of the alphabeta TCR Complex and Its
Co-Receptors. Front Immunol. 2014;5:583.
21. Schwartz RH. Historical overview of immunological tolerance. Cold Spring
Harb Perspect Biol. 2012;4(4):a006908.
22. Eisen HN, Schlesinger S. Remembrance of immunology past: conversations
with Herman Eisen. Annu Rev Immunol. 2015;33:1–28.
23. Mak TW. The T cell antigen receptor: “The Hunting of the Snark”. Eur J
Immunol. 2007;37 (Suppl 1):S83–93.
24. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion
with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad
Sci U S A. 1990;87(13):5031–5.
25. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4
is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;
174(3):561–9.
26. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science. 1970;
169(950):1042–9.
27. Lafferty KJ, Prowse SJ, Simeonovic CJ, Warren HS. Immunobiology of tissue
transplantation: a return to the passenger leukocyte concept. Annu Rev
Immunol. 1983;1:143–73.
28. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P,
Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for
the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71(7):1093–102.
29. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor
immunity. Immunol Today. 1993;14(10):483–6.
30. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM,
Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of
T cell activation. Immunity. 1994;1(5):405–13.
31. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer
immunotherapy. Adv Immunol. 2006;90:297–339.
32. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH.
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan
tissue destruction, revealing a critical negative regulatory role of CTLA-4.
Immunity. 1995;3(5):541–7.
33. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP,
Thompson CB, Griesser H, Mak TW. Lymphoproliferative disorders with early
lethality in mice deficient in Ctla-4. Science. 1995;270(5238):985–8.
34. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by
CTLA-4 blockade. Science. 1996;271(5256):1734–6.
35. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez
R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab
in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.
36. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain
JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously
untreated metastatic melanoma. N England J Med. 2011;364(26):2517–26.
37. Cameron F, Whiteside G, Perry C. Ipilimumab: first global approval. Drugs.
2011;71(8):1093–104.
38. Singh P, Pal SK, Alex A, Agarwal N. Development of PROSTVAC
immunotherapy in prostate cancer. Future Oncol. 2015;11(15):2137–48.
39. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner
MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28
monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018–28.
40. Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a
multidisciplinary approach. Oncologist. 2013;18(6):733–43.
41. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C,
Gogas H, Schachter J, Linette G, et al. Phase III randomized clinical trial
comparing tremelimumab with standard-of-care chemotherapy in patients
with advanced melanoma. J Clin Oncol. 2013;31(5):616–22.
42. Ibrahim RA, Berman DM, DePril V, Humphrey RW, Chen T, Messina M, Chin
KM, Liu HY, Bielefield M, Hoos A. Ipilimumab safety profile: Summary of
findings from completed trials in advanced melanoma. J Clin Oncol. 2011;
29(15_suppl):8583.
43. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE,
Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation
molecule eradicate established tumors. Nat Med. 1997;3(6):682–5.
44. Sanmamed MF, Pastor F, Rodriguez A, Perez-Gracia JL, Rodriguez-Ruiz ME,
Jure-Kunkel M, Melero I. Agonists of Co-stimulation in Cancer Immunotherapy
Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol.
2015;42(4):640–55.45. Chester C, Ambulkar S, Kohrt HE. 4-1BB agonism: adding the accelerator to
cancer immunotherapy. Cancer Immunol Immunother. 2016;65(10):1243–8.
46. Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, Coukos G, Powell Jr
DJ. CD137 accurately identifies and enriches for naturally occurring tumor-
reactive T cells in tumor. Clin Cancer Res. 2014;20(1):44–55.
47. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family,
co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med.
1999;5(12):1365–9.
48. Wang S, Zhu G, Chapoval AI, Dong H, Tamada K, Ni J, Chen L. Costimulation
of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood. 2000;96(8):
2808–13.
49. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G,
Tamada K, et al. B7-H3: a costimulatory molecule for T cell activation and
IFN-gamma production. Nat Immunol. 2001;2(3):269–74.
50. Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, Chapoval AI, Flies
DB, Bajorath J, Chen L. B7-H4, a molecule of the B7 family, negatively
regulates T cell immunity. Immunity. 2003;18(6):849–61.
51. Zhu Y, Yao S, Iliopoulou BP, Han X, Augustine MM, Xu H, Phennicie RT, Flies
SJ, Broadwater M, Ruff W, et al. B7-H5 costimulates human T cells via
CD28H. Nat Commun. 2013;4:2043.
52. Flies DB, Wang S, Xu H, Chen L. Cutting edge: A monoclonal antibody
specific for the programmed death-1 homolog prevents graft-versus-host
disease in mouse models. J Immunol. 2011;187(4):1537–41.
53. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-
cell immunity. Nat Rev Immunol. 2004;4(5):336–47.
54. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-
inhibition. Nat Rev Immunol. 2013;13(4):227–42.
55. Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory Pathways in
the B7-CD28 Ligand-Receptor Family. Immunity. 2016;44(5):955–72.
56. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu
J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell
apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):
793–800.
57. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ,
Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1
immunoinhibitory receptor by a novel B7 family member leads to negative
regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34.
58. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel
member of the immunoglobulin gene superfamily, upon programmed cell
death. EMBO J. 1992;11(11):3887–95.
59. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG,
Golstein P. A new member of the immunoglobulin superfamily–CTLA-4.
Nature. 1987;328(6127):267–70.
60. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like
autoimmune diseases by disruption of the PD-1 gene encoding an ITIM
motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51.
61. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai
Y, Long AJ, Brown JA, Nunes R, et al. PD-L2 is a second ligand for PD-1 and
inhibits T cell activation. Nat Immunol. 2001;2(3):261–8.
62. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, Shalabi A, Shin T,
Pardoll DM, Tsuchiya H. B7-DC, a new dendritic cell molecule with potent
costimulatory properties for T cells. J Exp Med. 2001;193(7):839–46.
63. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-
L1 on tumor cells in the escape from host immune system and tumor
immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):
12293–7.
64. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson
KL, Daniel B, Zimmermann MC, et al. Blockade of B7-H1 improves myeloid
dendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562–7.
65. Wang S, Bajorath J, Flies DB, Dong H, Honjo T, Chen L. Molecular modeling
and functional mapping of B7-H1 and B7-DC uncouple costimulatory
function from PD-1 interaction. J Exp Med. 2003;197(9):1083–91.
66. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed
death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule
to inhibit T cell responses. Immunity. 2007;27(1):111–22.
67. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D,
Cheville J, Hirano F, Lin W, et al. B7-H1 blockade augments adoptive T-cell
immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63(19):6501–5.
68. Dong H, Zhu G, Tamada K, Flies DB, van Deursen JM, Chen L. B7-H1
determines accumulation and deletion of intrahepatic CD8(+) T
lymphocytes. Immunity. 2004;20(3):327–36.
Wang et al. Journal of Hematology & Oncology  (2017) 10:34 Page 8 of 869. Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, Kuchroo VK,
Freeman GJ, Sharpe AH. PD-L1-deficient mice show that PD-L1 on T cells,
antigen-presenting cells, and host tissues negatively regulates T cells. Proc
Natl Acad Sci U S A. 2004;101(29):10691–6.
70. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB,
Lau JS, Zhu G, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies
potentiates cancer therapeutic immunity. Cancer Res. 2005;65(3):1089–96.
71. Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of
poorly immunogenic tumor cells by enhanced recruitment of effector T
cells. Int Immunol. 2005;17(2):133–44.
72. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman
GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic
viral infection. Nature. 2006;439(7077):682–7.
73. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH,
Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-
agent anti-programmed death-1 (MDX-1106) in refractory solid tumors:
safety, clinical activity, pharmacodynamics, and immunologic correlates. J
Clin Oncol. 2010;28(19):3167–75.
74. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF,
Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and
immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;
366(26):2443–54.
75. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG,
Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1
antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):
2455–65.
76. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP,
Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with
B7-h1 expression in human melanocytic lesions supports an adaptive resistance
mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra137.
77. Poole RM. Pembrolizumab: first global approval. Drugs. 2014;74(16):1973–81.
78. Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R. FDA Approval
Summary: Pembrolizumab for the Treatment of Patients With Metastatic
Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-
Ligand 1. Oncologist. 2016;21(5):643–50.
79. Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, Keegan P,
Pazdur R. FDA Approval Summary: Nivolumab for the Treatment of
Metastatic Non-Small Cell Lung Cancer With Progression On or After
Platinum-Based Chemotherapy. Oncologist. 2016;21(5):634–42.
80. Raedler LA. Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA
Approval for Unresectable or Metastatic Melanoma. Am Health Drug
Benefits. 2015;8(Spec Feature):180–3.
81. Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in
B-cell lymphomas. Nat Rev Clin Oncol. 2016. doi:10.1038/nrclinonc.2016.168.
82. Nods for Atezolizumab and Nivolumab from FDA. Cancer Discov. 2016;6(8):811.
83. Markham A. Atezolizumab: First Global Approval. Drugs. 2016;76(12):1227–32.
84. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the
treatment of advanced human cancer. Clin Cancer Res. 2013;19(5):1021–34.
85. Tontonoz M, Gee CE. Cancer immunotherapy out of the gate: the 22nd
annual Cancer Research Institute International Immunotherapy Symposium.
Cancer Immunol Res. 2015;3(5):444–8.
86. Selenko-Gebauer N, Majdic O, Szekeres A, Hofler G, Guthann E, Korthauer U,
Zlabinger G, Steinberger P, Pickl WF, Stockinger H, et al. B7-H1
(programmed death-1 ligand) on dendritic cells is involved in the induction
and maintenance of T cell anergy. J Immunol. 2003;170(7):3637–44.
87. Tsushima F, Yao S, Shin T, Flies A, Flies S, Xu H, Tamada K, Pardoll DM, Chen
L. Interaction between B7-H1 and PD-1 determines initiation and reversal of
T-cell anergy. Blood. 2007;110(1):180–5.
88. Goldberg MV, Maris CH, Hipkiss EL, Flies AS, Zhen L, Tuder RM, Grosso JF,
Harris TJ, Getnet D, Whartenby KA, et al. Role of PD-1 and its ligand, B7-H1,
in early fate decisions of CD8 T cells. Blood. 2007;110(1):186–92.
89. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK,
Sharpe AH. PD-L1 regulates the development, maintenance, and function of
induced regulatory T cells. J Exp Med. 2009;206(13):3015–29.
90. Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, Foley JE, Massey
PR, Felizardo TC, Riley JL, et al. The PDL1-PD1 axis converts human TH1 cells
into regulatory T cells. Sci Transl Med. 2011;3(111):111ra120.
91. Yao S, Wang S, Zhu Y, Luo L, Zhu G, Flies S, Xu H, Ruff W, Broadwater M,
Choi IH, et al. PD-1 on dendritic cells impedes innate immunity against
bacterial infection. Blood. 2009;113(23):5811–8.92. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous
antiapoptotic receptor on cancer cells. Blood. 2008;111(7):3635–43.
93. Petroff MG, Chen L, Phillips TA, Hunt JS. B7 family molecules: novel
immunomodulators at the maternal-fetal interface. Placenta. 2002;23(Suppl A):
S95–101.
94. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow
MA, Wolchok JD. Toxicities of the anti-PD-1 and anti-PD-L1 immune
checkpoint antibodies. Ann Oncol. 2015;26(12):2375–91.
95. Sharma P, Allison JP. The future of immune checkpoint therapy. Science.
2015;348(6230):56–61.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
